Bruker
Precision Oncology Dx Firm Navignostics Raises CHF 7.5 M in Seed Funding From Bruker, Others
The company is developing a system combining single-cell spatial proteomic data with artificial intelligence analysis to guide therapy selection for cancer patients.
New instruments with compact sizes and flexible pricing could help MALDI make inroads with smaller microbiology labs where it has had less of a presence to date.
PrognomiQ Closes $46M Financing Round
The firm, a spinoff of proteomics company Seer, said it will use the funds to accelerate its multiomic tests for cancer early detection, treatment selection, and patient monitoring.
A recent study by Swiss researchers showed that machine learning models can predict antibiotic susceptibility directly from MALDI-TOF mass spectra.
In Brief This Week: PerkinElmer, Labcorp, Illumina, Thermo Fisher Scientific, and More
News items for the in vitro diagnostics industry for the week of Nov. 15, 2021.